After a 57.4% rebound in Q1 followed by a narrow decline in April, Cannabis stocks, as measured by the Global Cannabis Stock Index, gave up substantial ground in May, declining...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$5.0 million per quarter. This...
This is a copy of the May 12th edition of our weekly Newsletter, which we have been publishing since October 2015. Friends, “The next Tilray”. This was a phrase...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019 Epidiolex U.S. Q1 net sales of $33.5m Positive Phase 3 pivotal results...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
This is a copy of the March 3rd edition of our weekly Newsletter, which we have been publishing since October 2015. Friends, Coming into its earnings report last Wednesday,...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the...
This is a copy of the February 24th edition of our weekly Newsletter, which we have been publishing since October 2015. Friends, On Friday, Statistics Canada provided its monthly...
A post on Twitter today has pressured GW Pharma (NASDAQ: GWPH), which dipped more than 3% to $145.21. The post, by Ryan Flinn, a Bay Area journalist in healthcare...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...
This is a copy of the October 7th edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, With fewer than two weeks until the...
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc...
GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON and CARLSBAD, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”),...
Cannabis stocks, as measured by the Global Cannabis Stock Index, added to their August gains in September, rising 2.4% to 114.83: The index, which had 53 qualifying members that were...
This is a copy of the September 30th edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, As we enter the final quarter of...
The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
This is a copy of the August 12th edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, GW Pharma (NASDAQ: GWPH) made history earlier...
GW Pharmaceuticals (NASDAQ: GWPH) released financials for its fiscal 2018 Q3 after the close today and hosted a conference call for investors and analysts. Readers can access a full...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter....
This is a copy of the July 1st edition of our weekly Newsletter, which we have been publishing since October, 2015. Friends, With 2018 now halfway behind us, we...
FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy June 25, 2018 The U.S. Food and Drug Administration today...
Clearstream, the Luxembourg-based central securities depository that provides the clearing for the German stock market, has informed its customers that it will no longer be possible to settle securities...
